Compass Therapeutics Gross Profit

The latest gross profit for CMPX is $-370K as of March 2026. That compares with $850K in the prior-year period — down 143.2% year over year. That is below the Healthcare sector average of $63B. Investors often review this figure alongside Compass Therapeutics's historical trend and sector peers before judging valuation or financial health.

Over the past year, CMPX's gross profit moved from $850K to $-370K — a 143.2% year-over-year decrease. If the trend continues in the same direction for several quarters, it can signal a meaningful shift in Compass Therapeutics's operating scale or balance-sheet position.

Against Healthcare companies, CMPX currently prints $-370K for gross profit, while the sector average sits near $63B. That is roughly 100.0% below the sector mean. Large gaps often invite a closer look at Compass Therapeutics's growth, margins, and balance sheet.

A gross profit figure of $-370K for CMPX is a snapshot of scale on that line item. On its own it does not say whether the business is healthy — you also want growth rate, margins, and how the number compares with similar companies. The Healthcare average is about $63B. Explore the charts below for those layers of context.

After noting CMPX's gross profit ($-370K), review year-over-year change from $850K, peer averages, and a few neighboring metrics such as revenue, margins, or valuation multiples. That combination usually beats staring at a single figure. The navigation links on this page jump you to those related views.